Impact of vitamin D deficiency on the clinical presentation and prognosis of patients with newly diagnosed multiple myeloma
Open Access
- 23 March 2009
- journal article
- research article
- Published by Wiley in American Journal of Hematology
- Vol. 84 (7), 397-400
- https://doi.org/10.1002/ajh.21412
Abstract
Vitamin D is a fundamental mediator of skeletal metabolism. It also has important nonskeletal actions. We hypothesized that vitamin D deficiency may play an important role in skeletal morbidity and clinical outcomes in MM. We studied 148 newly diagnosed MM patients from January 1, 2004 through December 31, 2008 who had a serum 25‐hydroxyvitamin D [25(OH)D] obtained within 14 days of diagnosis. Subjects with vitamin D deficiency [25(OH)D level less than 50 nmol/L (20 ng/mL)] had higher mean values of serum C‐reactive protein (CRP) (2.40 mg/L vs. 0.84 mg/L, P = 0.02) and creatinine (1.75 mg/dL vs. 1.24 mg/dL, P = 0.03) and lower serum albumin values (3.12 g/dL vs. 3.39 g/dL, P = 0.003) compared to subjects without vitamin D deficiency. The prevalence of vitamin D deficiency increased in parallel with International Staging System (ISS): 16% of subjects in Stage I, 20% in Stage II, and 37% in Stage III (P = 0.03) were vitamin D deficient. No differences were detected between the two groups in terms of skeletal morbidity. Association of vitamin D deficiency with higher serum CRP, serum creatinine and ISS stage at time of diagnosis suggests that vitamin D deficiency may portend poorer outcomes in subjects with MM. Am. J. Hematol. 2009.This publication has 27 references indexed in Scilit:
- Nonclassic Actions of Vitamin DJournal of Clinical Endocrinology & Metabolism, 2009
- Prevalence and significance of vitamin D deficiency in multiple myeloma patientsBritish Journal of Haematology, 2008
- Prognostic value of the serum free light chain ratio in newly diagnosed myeloma: proposed incorporation into the international staging systemLeukemia, 2008
- Vitamin D DeficiencyThe New England Journal of Medicine, 2007
- New Potential Targets for Treating Myeloma Bone DiseaseClinical Cancer Research, 2006
- International Staging System for Multiple MyelomaJournal of Clinical Oncology, 2005
- Mechanisms of Bone MetastasisThe New England Journal of Medicine, 2004
- Review of 1027 Patients With Newly Diagnosed Multiple MyelomaMayo Clinic Proceedings, 2003
- Induction of apoptosis by vitamin D3 analogue EB1089 in NCI‐H929 myeloma cells via activation of caspase 3 and p38 MAP kinaseBritish Journal of Haematology, 2000
- Cell Cycle Arrest Induced by the Vitamin D3 Analog EB1089 in NCI-H929 Myeloma Cells Is Associated with Induction of the Cyclin-Dependent Kinase Inhibitor p27Experimental Cell Research, 2000